On February 22, 2021 Micronoma, a San Diego, Calif.-based cancer detection biotech company reported that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology, closed a $3.5m convertible debt financing round (Press release, Micronoma, FEB 22, 2021, View Source [SID1234578332]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Backers included SymBiosis, LLC, and The Seerave Foundation. The investments bring the company’s total amount of funding to $6.5m since the first seed round six months ago.

Led by Sandrine Miller-Montgomery, CEO, Micronoma decrypts signals from some of the most ancient matter in the world, the microbiome, to detect cancer early, from all genomes.

The company intends to use the funds to complete its validation study on lung cancer prediction, set up CLIA (Clinical Laboratory Improvement Amendments) operations, establish its go-to-market strategy utilizing its Oncobiota platform, and initiate work on a second cancer target.